Cao Zhi-Gang, Zhou Hong-Wei, Peng Chao-Jin, Liu Mo, Du Yu, Yang Qing-Ming
Department of Hematology and Oncology, the First Affiliated Hospital of the People's Liberation Army General Hospital, Beijing 100048, P. R. China.
Chin J Cancer. 2013 Sep;32(9):520-3. doi: 10.5732/cjc.012.10221. Epub 2013 Apr 1.
At present, approximately 20% of Hodgkin lymphomas (HL) are relapsed and refractory, and therapeutic methods including chemotherapy, radiotherapy, and even stem cell transplantation are unsatisfactory. Brentuximab vedotin, composed of CD30 antibody and a chemotherapeutic agent, is a new targeted drug that eradicates tumor cells by binding to the CD30 antigen on their surface. In clinical trials, the response rate and complete remission rate of this drug were 73% and 40%, respectively, for relapsed and refractory HL. Here we report a case of CD30-positive relapsed and refractory HL that was treated with brentuximab. Before the treatment with brentuximab, the patient underwent chemotherapy, radiotherapy, and autologous stem cell transplantation. However, the disease continued to progress, affecting multiple organs and prompting symptoms such as persistent fever. After the treatment with brentuximab, the patient's condition improved. Body temperature returned to normal after 4 days. Lung nodules were reduced in size and number after a single course of treatment, and PET/CT showed partial remission and complete remission after 3 and 6 courses of treatment, respectively. The entire treatment process progressed smoothly, though the patient experienced some symptoms due to chemotherapy, including peripheral neuritis of the limbs, irritating dry cough, and mild increase in aminotransferase. No serious adverse effects were observed. The current general condition of the patient is good; the continuous complete remission has amounted to 6 months.
目前，约20%的霍奇金淋巴瘤（HL）会复发且难治，包括化疗、放疗甚至干细胞移植在内的治疗方法均不尽人意。本妥昔单抗由CD30抗体和一种化疗药物组成，是一种新型靶向药物，通过与肿瘤细胞表面的CD30抗原结合来根除肿瘤细胞。在临床试验中，该药物用于复发难治性HL的缓解率和完全缓解率分别为73%和40%。在此，我们报告一例用本妥昔单抗治疗的CD30阳性复发难治性HL病例。在用本妥昔单抗治疗前，患者接受了化疗、放疗和自体干细胞移植。然而，疾病仍持续进展，累及多个器官并引发持续发热等症状。使用本妥昔单抗治疗后，患者病情改善。4天后体温恢复正常。单疗程治疗后肺结节大小和数量减少，PET/CT显示分别在3个和6个疗程治疗后部分缓解和完全缓解。整个治疗过程进展顺利，不过患者出现了一些化疗相关症状，包括四肢周围神经炎、刺激性干咳和转氨酶轻度升高。未观察到严重不良反应。患者目前一般状况良好；持续完全缓解已达6个月。
